🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

22 results for “Eisai Co.,” Clear

  1. E0302 (mecobalamin)

    Eisai Co.,

    Amyotrophic Lateral Sclerosis (ALS)

    phase 3 small molecule completed

    1 trial

  2. LECANEMAB

    Eisai Co.,

    Early Preclinical Alzheimer’s Disease and Intermediate Amyloid, Preclinical Alzheimer’s Disease and Elevated Amyloid

    phase 3 small molecule active

    1 trial

  3. Lecanemab

    Eisai Co.,

    Mild cognitive impairment due to Alzheimer's disease or mild Alzheimer's disease dementia.

    phase 3 small molecule active

    1 trial

  4. Pembrolizumab

    Eisai Co.,

    Endometrial Neoplasms

    phase 3 small molecule completed

    1 trial

  5. Zonisamide

    Eisai Co.,

    Epilepsy

    phase 3 small molecule completed

    1 trial

  6. bexarotene

    Eisai Co.,

    Non-small Cell Lung Cancer

    phase 3 small molecule completed

    1 trial

  7. perampanel

    Eisai Co.,

    Epilepsy

    phase 3 small molecule completed

    2 trials

  8. An Open-label, Multicenter, Phase 2 Dose Optimization and Expansion Study to Evaluate the Safety and Efficacy of BB-1701, an anti-human epidermal growth factor receptor 2 (anti-HER2) antibody-drug conjugate (ADC), in Previously Treated Subjects with HER2-positive or HER2-low Unresectable or Metastatic Breast Cancer

    Eisai Co.,

    HER2 positive or HER2-low metastatic breast cancer

    phase 2 other active

    1 trial

  9. E7080

    Eisai Co.,

    Solid Tumors

    phase 2 small molecule completed

    1 trial

  10. E7090

    Eisai Co.,

    Cholangiocarcinoma

    phase 2 small molecule completed

    1 trial

  11. E7386, Doxorubicin EBEWE 2 mg/ml koncentratas infuziniam tirpalui, E7386, Паклитаксел Ебеве 6 mg/ml концентрат за инфузионен разтвор, Paclitaxel Aurobindo 6 mg/ml concentrato per soluzione per infusione, Doxorubicina Aurobindo 2 mg/ml concentrato per soluzione per infusione, LENVIMA 10 mg hard capsules, LENVIMA 4 mg hard capsules

    Eisai Co.,

    Hepatocellular carcinoma, colorectal cancer, endometrial cancer, or other solid tumor

    phase 2 small molecule active

    1 trial

  12. FOLFIRI

    Eisai Co.,

    Colon Cancer

    phase 2 small molecule terminated

    1 trial

  13. Fycompa 2 mg film-coated tablets, Fycompa 2 mg film-coated tablets, Fycompa 0.5 mg/ml oral suspension, Fycompa 2 mg film-coated tablets

    Eisai Co.,

    Childhood Epilepsy

    phase 2 small molecule active

    1 trial

  14. LENVIMA 4 mg hard capsules, E7386, KEYTRUDA 25 mg/mL concentrate for solution for infusion, E7386, LENVIMA 10 mg hard capsules

    Eisai Co.,

    colorectal cancer, melanoma, hepatocellular carcinoma

    phase 2 small molecule active

    1 trial

  15. Lenvatinib

    Eisai Co.,

    Osteosarcoma

    phase 2 small molecule completed

    1 trial

  16. Tazemetostat

    Eisai Co.,

    Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma

    phase 2 small molecule completed

    1 trial

  17. eribulin mesylate + erlotinib

    Eisai Co.,

    Non-small Cell Lung Cancer

    phase 2 small molecule completed

    1 trial

  18. farletuzumab ecteribulin, LENVIMA 4 mg hard capsules, LENVIMA 10 mg hard capsules

    Eisai Co.,

    Solid tumors in 4 tumor types: platinum resistant ovarian cancer, triple-negative breast cancer (TNBC), endometrial cancer (EC), and non-small cell lung cancer adenocarcinoma; NSCLC).

    phase 2 small molecule active

    1 trial

  19. E0302 SR1

    Eisai Co.,

    Healthy Subjects

    phase 1 small molecule completed

    1 trial

  20. E6007

    Eisai Co.,

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial

  21. E7080

    Eisai Co.,

    Cancer: Solid Tumors

    phase 1 small molecule completed

    1 trial

  22. E7766

    Eisai Co.,

    Lymphoma

    phase 1 small molecule terminated

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources